Trials / Completed
CompletedNCT05428943
OPT101 in Type 1 Diabetes Patients
A Phase 1b Study of OPT101 in Patients With Type 1 Diabetes
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Op-T LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1b designed to assess safety, pharmacokinetics, immunological and clinical effects of multiple ascending doses of OPT101.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OPT101 | 15-mer peptide derived from the sequence of mouse CD154. |
Timeline
- Start date
- 2022-09-27
- Primary completion
- 2024-02-21
- Completion
- 2024-02-21
- First posted
- 2022-06-23
- Last updated
- 2024-05-03
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05428943. Inclusion in this directory is not an endorsement.